PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in September:
H.C. Wainwright 25th Annual Global Investment Conference — September 11-13, 2023
- Presentation: Tuesday, September 12th at 10:00 AM ET
- Webcast Link: https://journey.ct.events/view/b77088e1-4859-49a5-bdbe-353a3774b1ba
2023 Cantor Fitzgerald Global Healthcare Conference — September 26 - 28, 2023
- Fireside Chat: Tuesday, September 26th at 8:35 AM ET
- Webcast Link: https://wsw.com/webcast/cantor19/urgn/2115036
Webcasts for both conferences will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. JELMYTO® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.